synaptogenesis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-09. Numbers and descriptions here follow the published literature rather than marketing material.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
The discovery of estrogen is usually credited to the American scientists Edgar Allen and Edward A. Doisy. In 1923, they observed that injection of fluid from porcine ovarian follicles produced pubertal- and estrus-type changes (including vaginal, uterine, and mammary gland changes and sexual receptivity) in sexually immature, ovariectomized mice and rats. These findings demonstrated the existence of a hormone which is produced by the ovaries and is involved in sexual maturation and reproduction. At the time of its discovery, Allen and Doisy did not name the hormone, and simply referred to it as an "ovarian hormone" or "follicular hormone"; others referred to it variously as feminin, folliculin, menformon, thelykinin, and emmenin. In 1926, Parkes and Bellerby coined the term estrin to describe the hormone on the basis of it inducing estrus in animals. Estrone was isolated and purified independently by Allen and Doisy and German scientist Adolf Butenandt in 1929, and estriol was isolated and purified by Marrian in 1930; they were the first estrogens to be identified. Estradiol, the most potent of the three major estrogens, was the last of the three to be identified. It was discovered by Schwenk and Hildebrant in 1933, who synthesized it via reduction of estrone. A few milligrams of estradiol was subsequently isolated and purified from 4 tons of sow ovaries by Doisy in 1935, with its chemical structure determined simultaneously, and was referred to variously as dihydrotheelin, dihydrofolliculin, dihydrofollicular hormone, and dihydroxyestrin.
=== Phase 3 === Clomipramine/sildenafil (CDFR-0812) – combination of clomipramine (tricyclic antidepressant (TCA), serotonin–norepinephrine reuptake inhibitor (SNRI), other actions) and sildenafil (phosphodiesterase PDE5 inhibitor) – premature ejaculation [5] Gepirone (Ariza; BMY-13805-1; BMY-13805; Exxua; Gepirone ER; MJ-13805; Org-33062; TGFK07AD; Travivo; Variza) – serotonin 5-HT1A receptor agonist, other actions – decreased libido [6] Nitroglycerin gel (Eroxon; glyceryl trinitrate topical gel; MED-2001; MED-2003; MED-2004; MED-2005; MED-3000; MED2002) – guanylate cyclase stimulant, nitric oxide donor, nitric oxide stimulant – erectile dysfunction [7] Prasterone vaginal (dehydroepiandrosterone; DHEA; Intrarosa; Vaginorm) – androgen (androgen receptor agonist), other actions – decreased libido [8] Sacubitril/valsartan (AHU-377/valsartan; Enrest; Enresuto; Entresto; Entresto Sprinkle; LCZ-696; LCZ-696A; Neparvis; valsartan/AHU-377; valsartan/sacubitril) – combination of sacubitril (neprilysin inhibitor) and valsartan (angiotensin II receptor type 1 (AT1) antagonist) – erectile dysfunction [9]
Human studies identify the risk of cognitive impairments and decline (dementia) including the Alzheimer's type. Diabetic cardiomyopathy, damage to the heart muscle, leading to impaired relaxation and filling of the heart with blood (diastolic dysfunction) and eventually heart failure; this condition can occur independent of damage done to the blood vessels over time from high levels of blood glucose. Erectile Dysfunction, Men with erectile dysfunction and those with diabetes are likely to have experienced the problem as much as 10 to 15 years earlier than men without and are at a significantly higher risk, with a prevalence rate of 52.5%, 3.5-fold higher than those without DM. And defined as a consistent inability to have an erection firm enough for sexual intercourse. Women may also experience forms of sexual dysfunction due to damage to small blood vessels and nerves. Periodontal disease (gum disease): is associated with diabetes Diabetes is a substantial risk factor for periodontitis, with diabetics having a threefold higher risk than non-diabetics. In assessing increased risk, glycemic control is essential. Research primarily focuses on type 2 diabetes, but type 1 diabetes also increases risk, particularly in children and young people.
Schleswig-Holstein () is a coastal state that is the northernmost of the sixteen states of Germany, comprising most of the historical Duchy of Holstein and the southern part of the former Duchy of Schleswig. It borders Denmark, Mecklenburg-Vorpommern, Lower Saxony and the city-state of Hamburg. Its capital city is Kiel; other notable cities are Lübeck and Flensburg. It covers an area of 15,763 km2 (6,086 sq mi), making it the 5th smallest German state by area (including the city-states). Historically, the name can also refer to a larger region, containing both present-day Schleswig-Holstein and the former South Jutland County (Northern Schleswig; now part of the Region of Southern Denmark) in Denmark. Schleswig, known as South Jutland at the time, had been under Danish control since the fifth century. In the 12th century, however, it became a duchy within Denmark due to infighting in the Danish royal house. It bordered Holstein, which was a part of the Holy Roman Empire. Beginning in 1460, the King of Denmark ruled both Schleswig and Holstein as their duke. Schleswig was still part of Denmark, while Holstein remained part of the Holy Roman Empire. In the 19th century, both Danes and Germans believed they had a rightful claim to Schleswig-Holstein. While the population of Holstein and Lauenburg was entirely ethnically German, Schleswig had been predominantly Danish until the late 1700s and early 1800s, when extensive German influence led to the Germanization of South Schleswig.
=== Computing === Hyperlink, from one electronic document to another link (Unix), a command-line program to link directory entries <link>, a type of HTML element Link, in a linked list Linker (computing), a program which converts object files to an executable Links (web browser) Microsoft Office Assistant Links, an animated cat Link layer in computer networking ln (Unix), a command-line program to create a link to a file Chainlink (blockchain), a cryptocurrency Link, an Internet wallet service from Stripe, Inc.
Sources: en.wikipedia.org
=== Digestive system === Somatostatin is secreted by delta cells at several locations in the digestive system, namely the pyloric antrum, the duodenum and the pancreatic islets. Somatostatin released in the pyloric antrum travels via the portal venous system to the heart, then enters the systemic circulation to reach the locations where it will exert its inhibitory effects. In addition, somatostatin release from delta cells can act in a paracrine manner. In the stomach, somatostatin acts directly on the acid-producing parietal cells via a G-protein coupled receptor (which inhibits adenylate cyclase, thus effectively antagonising the stimulatory effect of histamine) to reduce acid secretion. Somatostatin can also indirectly decrease stomach acid production by preventing the release of other hormones, including gastrin and histamine which effectively slows down the digestive process.
==== Parafollicular cells ==== Scattered among follicular cells and in spaces between the spherical follicles are another type of thyroid cell, parafollicular cells. These cells secrete calcitonin and so are also called C cells.
From the time of Maria Theresa (1740−1780) onward, Tyrol was governed by the central government of the Habsburg monarchy at Vienna in all matters of major importance. In 1803 the lands of the Prince-Bishoprics of Trent and Brixen were secularised and incorporated into the county.
Many of these interactions and effects cause stress in the fish, which can be a major factor in facilitating fish disease. For many parasites, infestation depends on the host's degree of mobility, the density of the host population and vulnerability of the host's defence system. Sea lice are the primary parasitic problem for finfish in aquaculture, high numbers causing widespread skin erosion and haemorrhaging, gill congestion, and increased mucus production. There are also a number of prominent viral and bacterial pathogens that can have severe effects on internal organs and nervous systems.
Sources: en.wikipedia.org
==== Urinary system ==== The urinary system is the part of the excretory system that removes waste in the form of urine, comprising the kidneys, ureters, bladder, and the urethra. Other purposes of the urinary system include the regulation of blood volume and blood pressure; the control of electrolyte and metabolite levels; and the regulation of blood pH. Each kidney consists of functional units called nephrons. Following filtration of blood and further processing, the ureters carry urine from the kidneys into the urinary bladder. During urination, the urethra carries urine out of the bladder through the penis or vulva. The female and male urinary system are very similar, differing only in the length of the urethra.
Community design and reliance on automobiles have been linked to obesity risk. A walkability index developed for Atlanta-area communities found that residents of the most walkable neighborhoods were 2.4 times more likely to get recommended amounts of physical activity than those in the least walkable areas. A follow-up study found that a 5% increase in a community's walkability index was associated with a 32.1% increase in time spent walking or biking and a 0.23-point reduction in BMI. Worldwide there has been a large shift towards less physically demanding work, and currently at least 30% of the world's population gets insufficient exercise. This is primarily due to increasing use of mechanized transportation and a greater prevalence of labor-saving technology in the home. In children, there appear to be declines in levels of physical activity (with particularly strong declines in the amount of walking and physical education), likely due to safety concerns, changes in social interaction (such as fewer relationships with neighborhood children), and inadequate urban design (such as too few public spaces for safe physical activity). World trends in active leisure time physical activity are less clear. The World Health Organization indicates people worldwide are taking up less active recreational pursuits, while research from Finland found an increase and research from the United States found leisure-time physical activity has not changed significantly. Physical activity in children may not be a significant contributor.
=== Biochemical carbon concentrating mechanisms === Biochemical CCMs concentrate carbon dioxide in one temporal or spatial region, through metabolite exchange. C4 and CAM photosynthesis both use the enzyme Phosphoenolpyruvate carboxylase (PEPC) to add CO2 to a 4-carbon sugar. PEPC is faster than RuBisCO, and more selective for CO2.
Toldt's fascia, is a discrete layer of connective tissue containing lymphatic channels. It is found between the two mesothelial layers that separate the mesocolon from the underlying retroperitoneum. It was first described by the Austrian anatomist Carl Toldt (1840–1920) as a fascial plane formed by the fusion of the visceral peritoneum with the parietal peritoneum. This was later called Toldt's fascia.
=== Sense of self and self-concept === Individuals diagnosed with BPD frequently experience significant difficulties in maintaining a stable self-concept. This identity disturbance manifests as uncertainty in personal values, beliefs, preferences, and interests. They may also express confusion regarding their aspirations and objectives in terms of relationships and career paths. Such indeterminacy leads to feelings of emptiness and a profound sense of disorientation regarding their own identity. Moreover, their self-perception can fluctuate dramatically over short periods, oscillating between positive and negative evaluations. Consequently, individuals with BPD might adopt their sense of self based on their surroundings or the people they interact with, resulting in a chameleon-like adaptation of identity, known as mirroring. This can also often lead to pervasive emotional contagion.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.